A OPEN LABEL STUDY OF THE EFFICACY AND SAFETY OF PD0332991 A SELECTIVE INHIBITOR OF THE CYCLIN DEPENDENT KINASES 4 AND 6 IN PATIENTS WITH RECURRENT OVARIAN CANCER DEMONSTRATING RB-PROFICIENCY AND LOW P16 EXPRESSION: